This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: National Institute of Health and Medical Research, Université De La Méditerranée - Aix-Marseille Ii. Active years: 2013.
Company Filing History:
1 out of 1,853 
1 out of 10 Years Active: 2013
Title: Martin Krahn: Innovator in Dysferlinopathy Treatment
Introduction
Martin Krahn is a notable inventor based in Marseille, France. He has made significant contributions to the field of genetic therapies, particularly in the treatment of dysferlinopathies. His innovative approach focuses on restoring the function of mutated dysferlin, which is crucial for muscle function.
Latest Patents
Krahn holds a patent for "Exon skipping therapy for dysferlinopathies." This invention relates to methods for restoring the function of a mutated dysferlin by preventing the splicing of one or more exons that encode amino acid sequences causing dysferlin dysfunction. Specifically, the splicing of exon 32 is targeted. The patent also outlines a method for treating dysferlinopathy in patients by administering antisense oligonucleotides that are complementary to nucleic acid sequences necessary for correct splicing.
Career Highlights
Throughout his career, Martin Krahn has worked with esteemed institutions such as the Institut National de la Santé et de la Recherche Médicale and Université de la Méditerranée—Aix-Marseille II. His work has been pivotal in advancing therapeutic strategies for genetic disorders.
Collaborations
Krahn has collaborated with notable colleagues, including Nicolas Levy and Marc Bartoli. These partnerships have contributed to the development of innovative solutions in the field of genetic research.
Conclusion
Martin Krahn's work in exon skipping therapy represents a significant advancement in the treatment of dysferlinopathies. His innovative methods and collaborations continue to pave the way for future research and therapies in genetic disorders.